SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L11%, as determined by an FDA-approved test.
Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity to receive immunotherapy to increase their chances for cure, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. Todays landmark approval gives physicians and patients a new way to treat early lung cancer that has the potential to significantly reduce risk of cancer recurrence, after more than a decade with limited treatment advances in this setting.
Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse, said Bonnie Addario, Co-founder and Chair, GO2 Foundation for Lung Cancer. With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.
The approval is based on results from an interim analysis of the Phase III IMpower010 study that showed treatment with Tecentriq following surgery and platinum-based chemotherapy reduced the risk of disease recurrence or death by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50-0.88) in people with Stage II-IIIA (UICC/AJCC 7th edition) NSCLC whose tumors express PD-L11%, compared with best supportive care (BSC). Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified. Fatal and serious adverse reactions occurred in 1.8% and 18%, respectively, of patients receiving Tecentriq. The most frequent serious adverse reactions (>1%) were pneumonia (1.8%), pneumonitis (1.6%), and pyrexia (1.2%).
The review of this application was conducted under the FDAs Project Orbis initiative, which provides a framework for concurrent submission and review of oncology medicines among international partners. According to the FDA, collaboration among international regulators may allow patients with cancer to receive earlier access to products in other countries where there may be significant delays in regulatory submissions. Simultaneous applications were submitted to regulators in the United States, Switzerland, the United Kingdom, Canada, Brazil and Australia under Project Orbis. Additionally, the FDA reviewed and approved the supplemental application under its Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.
Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the U.S. In addition to becoming the first approved cancer immunotherapy for adjuvant NSCLC, Tecentriq was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy). Tecentriq also has four approved indications in advanced NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies. Tecentriq is available in three dosing options, providing the flexibility to choose administration every two, three or four weeks.
Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across different lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumor types.
About the IMpower010 study
IMpower010 is a Phase III, global, multicenter, open-label, randomized study evaluating the efficacy and safety of Tecentriq compared with BSC, in participants with Stage IB-IIIA NSCLC (UICC/AJCC 7th edition), following surgical resection and up to 4 cycles of adjuvant cisplatin-based chemotherapy. The study randomized 1,005 people with a ratio of 1:1 to receive either Tecentriq for 1 year (16 cycles), unless disease recurrence or unacceptable toxicity occurred, or BSC. The primary endpoint is investigator-determined DFS in the PD-L1-positive Stage II-IIIA, all randomized Stage II-IIIA and intent-to-treat (ITT) Stage IB-IIIA populations. Key secondary endpoints include overall survival (OS) in the overall study population, ITT Stage IB-IIIA NSCLC.
About lung cancer
According to the American Cancer Society, it is estimated that more than 235,000 Americans will be diagnosed with lung cancer in 2021. NSCLC accounts for 80-85% of all lung cancers and approximately 50% of patients diagnosed with NSCLC are diagnosed with early-stage (Stages I and II) or locally advanced (Stage III) disease. Today, about half of all people with early lung cancer still experience a cancer recurrence following surgery. Treating lung cancer early, before it has spread, may help prevent the disease from returning and provide people with the best opportunity for a cure.
About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.
Tecentriq U.S. Indications
Tecentriq is a prescription medicine used to treat adults with:
A type of lung cancer called non-small cell lung cancer (NSCLC).
A type of lung cancer called small cell lung cancer (SCLC).
It is not known if Tecentriq is safe and effective in children.
Important Safety Information
What is the most important information about Tecentriq?
Tecentriq can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become severe or life threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during their treatment or even after their treatment has ended.
Patients should call or see their healthcare provider right away if they develop any new or worse signs or symptoms, including:
Hormone gland problems
Problems can also happen in other organs.
These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including:
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if patients undergo transplantation either before or after being treated with Tecentriq. A healthcare provider will monitor for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects.
Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:
Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Tecentriq when used alone include:
The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:
Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.
These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq.
Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Report side effects to Genentech at 1-888-835-2555.
Please see http://www.Tecentriq.com for full Prescribing Information and additional Important Safety Information.
About Genentech in cancer immunotherapy
Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system.
In addition to Genentechs approved PD-L1 checkpoint inhibitor, the companys broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy.
About Genentech in lung cancer
Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
See the article here:
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021
- TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition - GlobeNewswire - December 4th, 2021
- Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA... - December 3rd, 2021
- Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire - December 3rd, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - PRNewswire - December 3rd, 2021
- Treatment Tricks Cancer Cells Into Changing Their Identity To Eliminate Them - Technology Networks - December 3rd, 2021
- Soumit K. Basu MD PhD is recognized by Continental Who's Who - The Wellsboro Gazette - December 3rd, 2021
- Report of Placebo-Controlled Clinical Trial Evaluating MultiStem Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care... - November 30th, 2021
- Restorative treatments for erectile dysfunction arent proven to work. Men pay thousands anyway. - The Philadelphia Inquirer - November 30th, 2021
- Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma - Yahoo Finance - November 30th, 2021
- Letter to the editor | In support of Hakeem Jefferson and the Early Career Black Faculty Group - The Stanford Daily - November 30th, 2021
- Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning - Seeking Alpha - November 30th, 2021
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 28th, 2021
- How drugs are reviewed and approved in Canada - The Globe and Mail - November 27th, 2021
- JGC : Investment in two companies in the MSC regenerative medicine and digital therapeutics fields through CVC fund - marketscreener.com - November 27th, 2021
- Global Cell Therapy Manufacturing Market Report 2021, Featuring Key Players KBI Biopharma, Waisman Biomanufacturing, Merck and Thermo Fisher... - November 27th, 2021
- Digital twins for predictive oncology will be a paradigm shift for precision cancer care - Nature.com - November 27th, 2021
- From tummy tucks to facelifts: Pet plastic surgery is happening in Ohio - NewsNation Now - November 27th, 2021
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 24th, 2021
- Global Cell Therapy Markets Report 2021-2030: Cell Therapy Markets According to Therapeutic Areas, Technologies, & Companies - PRNewswire - November 24th, 2021
- Research Developments in the Treatment of Advanced Kidney Cancer - liherald - November 24th, 2021
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 24th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 24th, 2021
- UoH start-up ties up with GenepoweRx for personalizing medical procedures - United News of India - November 24th, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- FDA Action Alert: Takeda, Aadi and Fennec - BioSpace - November 22nd, 2021
- New MedHouse Location Opens in West Palm Beach, Powered by R3 Health: Popular Concierge Membership Social Wellness and Biohacking Club Welcomes New... - November 22nd, 2021
- Researchers use model of hypothalamus to implicate genes associated with sleep, BMI, puberty, and more - EurekAlert - November 21st, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome -... - November 21st, 2021
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 18th, 2021
- Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases - PRNewswire - November 18th, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim ... - The Bakersfield Californian - November 18th, 2021
- Diabetes breakthrough: Revolutionary stem cell technique treated 'severe' disease in study - Daily Express - November 18th, 2021
- French biotech CellProthera welcomes three exceptional talents to its executive management team - Business Wire - November 18th, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 18th, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture -... - November 18th, 2021
- PhD Studentship, Cartilage Regenerative Medicine job with UNIVERSITY OF SOUTHAMPTON | 271677 - Times Higher Education (THE) - November 16th, 2021
- Behind the FDA Approval: Belumosudil for Chronic Graft Versus Host Disease - Targeted Oncology - November 16th, 2021
- Dr. Nathan Newman Recognized as a Professional of the Year for 2021 by Strathmore's Who's Who Worldwide - PR.com - November 16th, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 16th, 2021
- miRNA-based therapeutics to treat Glioblastoma at Johns Hopkins Medical Institute in Baltimore - Open Access Government - November 16th, 2021
- New dates announced for global scientific conference recruited to Memphis by UT Health Science Center and Tennessee Institute of Regenerative Medicine... - November 13th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 13th, 2021
- ASCO Reading Room | CAR T-Cell Therapy in Hematologic Malignancies | MedPage Today - MedPage Today - November 13th, 2021
- This Week at FDA: CDRH and Endologix leaks, OTC monograph reform, and more - Regulatory Focus - November 13th, 2021
- Always Ready: A military man's motto on service and cancer - Yale School of Medicine - November 13th, 2021
- 100 years after insulin treatment was invented, researchers hope to ditch needles once and for all - CBC.ca - November 13th, 2021
- These 5 Things Can Cause Your Hip to Collapse Eat This Not That - Eat This, Not That - November 13th, 2021
- Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios KK - GuruFocus.com - November 13th, 2021
- Putting the move back in movement - Scope - Scope - November 11th, 2021
- Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy - InvestorIntel - November 11th, 2021
- Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market... - November 11th, 2021
- It takes a village (of cells) to heal the intestine - Baylor College of Medicine News - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference -... - November 11th, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 9th, 2021
- UM teams to research under-studied aspects of COVID-19 - UM Today - November 9th, 2021
- COVID Booster Eligibility: Who Can Get the Third Vaccine Dose Now? - NBC10 Boston - November 9th, 2021
- He cant cure his dad. But a scientists research may help everyone else. - The Indian Express - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - Yahoo Finance - November 9th, 2021
- MS in Stem Cell Biology and Regenerative Medicine - November 7th, 2021
- Institute for Stem Cell & Regenerative Medicine ... - November 7th, 2021
- Stem-cell niche - Wikipedia - November 7th, 2021
- Stem Cell Network - November 7th, 2021
- This is such an important moment: how stem cell research ... - November 7th, 2021
- Experts gain insights into pathomechanisms of dilated cardiomyopathy - News-Medical.Net - November 7th, 2021
- Updates in Therapies of Relapsed and Refractory Follicular Lymphoma - Cancer Network - November 7th, 2021
- Totipotent Stem Cell - an overview | ScienceDirect Topics - November 7th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 5th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 5th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 5th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - WDRB - November 5th, 2021
- Clade Therapeutics Raises $87 Million Series A Financing to - GlobeNewswire - November 5th, 2021